Dr. Laura Finn brings new treatment options to Louisiana using genetically altered cells to treat blood cancer patients. Here ...

Another man can now move his arms and legs following the treatment ... pluripotent stem (iPS) cells are created by reverting adult cells to an embryonic-like state, from which they can be coaxed ...

He not only highlighted the success stories of using adult stem cell therapy and platelet-rich plasma therapy in treating patients with conditions such as stroke, arthritis, cerebral palsy ...

Once damaged, it has limited ability to heal, leaving millions of people worldwide with permanent paralysis. However, a groundbreaking clinical trial in Japan has provided a glimmer of hope, showing ...

A Japanese patient paralyzed for years can now stand unaided after participating in a groundbreaking clinical trial using ...

Techniques that cause multipotent adult mesenchymal stem cells (MSCs) to differentiate ... activities in the OA joint. Targeted gene therapy might further enhance these activities of MSCs.

Keio University researchers used induced pluripotent stem cells (iPS cells) created by stimulating mature, specialized cell ...

Beyond gene therapy, another issue of much debate relates to the use of stem cells. These cells can be divided into two broad classes: embryonic and adult. Both classes are currently being ...

In partnership with the National Institute of Allergy and Infectious Diseases, we committed nearly $4 million over five years to co-fund a major study of mesenchymal (adult) stromal cells as a new ...

Cytora, a clinical stage company developing unique stem cell treatments based on human Oral Mucosa Stem Cells (hOMSCs), reported today successful results of a Phase 1/2a clinical trial for treating ...

The scientists predicted these new cells could be the key to regenerative treatments for serious injuries ... discovering that they could reprogram adult cells to return to their pluripotent ...

A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a CD30/CD16A bispecific antibody, was safe and generated strong response rates ...